

Attorney Docket No. 401544/MATHISEN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of:

DEC 3-0 2002

RATLEDGE et al.

Art Unit: 1633

TECH CENTER 1600/2900

Application No.: 10/030,700

Examiner: Unassigned

Filed: January 14, 2002

For:

CULTURE OF CRYPTHECODINIUM COHNII FOR THE SYNTHESIS OF A POLYUNSATURATED FATTY ACID

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

13.2.

In re Appln. of: RATLEDGE et al.

Application No. 10/030,700 after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes one of: the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below). П after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). П after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed. Copies of the References Ø Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). 図 A copy of the United Kingdom search report is enclosed herewith. \Box The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining

references were previously furnished are set out below:

Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the

In re Appln. of: RATLEDGE et al. Application No. 10/030,700

	U.S. APPLICATIONS Status (check one)						
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED		
1.							
2.							
3.							
State	ment under 37 CFR	1.97(e)					
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.						
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.						
State	Statement under 37 CFR 1.704(d)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.						
Fees							
	No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.						
Method of Payment of Fees							
	Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ this communication is enclosed for that purpose.) (A duplicate copy of						
Autho	Authorization to Charge Additional Fees						
\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)						

In re Appln. of: RATLEDGE et al. Application No. 10/030,700

Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

Respectfully submitted,

Xavier Pillai, Reg. No. 39,799 LEYDIG, VOIT & MAYER

700 Thirteenth Street, N.W., Suite 300

Washington, DC 20005-3960 (202) 737-6770 (telephone) (202) 737-6776 (facsimile)

IDS (Rev. 7/11/2002)

Date: /2/27/02

Substitute for form 1449A/B/PTO

Sheet

TENT & TRADE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

Complete if Known **Application Number** 10/030,700 Filing Date January 14, 2002 RATLEDGE et al. First Named Inventor **Group Art Unit** 1633 Unassigned **Examiner Name** Attorney Docket Number 401544

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Application or Examiner Kind Filing Date If Doc. No. Name of Patentee or Applicant Initials Patent Number Code Appropriate C 1 3,444,647 Takahashi 05/20/69

	•			FOREIG	N PATENT DOCUMENTS			
		Foreign Patent Document		nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*1
-	C 2		JP 7-87988		Kenichi et al.	04/04/95		+
					<u> </u>			├
				 			<u> </u>	╂
				+	-			+

		OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Translation	
	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+	
	C 3	A. G. CALLELY et al.; "The Metabolism of Propionate in the Colourless alga, Prototheca zopfii"; Biochem. Journal (1964), Vol. 92, pp. 338-345	_		
		·			

Examiner Signature		nsidered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).